GenSight participated to NANOS 42nd Annual Meeting in Tucson (AZ), US.

Dr Catherine Vignal, Head chief at the Rothschild Ophthalmological Foundation, MD in XV-XX Hospital, Paris, will give a talk on ” Recombinant AAV2 Containing the Wild-Type ND4 Gene (rAAV2/2-ND4) is an Experimental Gene Therapy for Vision Loss in LHON Due to the ND4 Mitochondrial Mutation: Phase I/IIa Safety Investigation Results and Upcoming Pivotal Phase III Efficacy Studies “.